RAD50 targeting impairs DNA damage response and sensitizes human breast cancer cells to cisplatin therapy

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277 - 300; http://dx.doi.org/10.3322/caac.20073; PMID: 20610543
   PubMed Web of Science ®Google Scholar
• Colozza M, Gori S, Mosconi AM, Belsanti V, Basurto C, Rossetti R, Di Costanzo F, Buzzi F, Bacchi M, Davis S, et al. Chemotherapy with cis-platin, doxorubicin, and cyclophosphamide (CAP) in patients with metastatic breast cancer. Am J Clin Oncol 1989; 12:137 - 41; http://dx.doi.org/10.1097/00000421-198904000-00010; PMID: 2705403
   PubMed Web of Science ®Google Scholar
• Lin C, Chen DR, Chang KJ, Chang TW, Wang HC. A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin and trastuzumab for T2 breast cancers. Cancer Chemother Pharmacol 2012; 69:1363 - 8; http://dx.doi.org/10.1007/s00280-012-1841-y; PMID: 22349922
   PubMed Web of Science ®Google Scholar
• Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep 2003; 10:1663 - 82; PMID: 14534679
   PubMed Web of Science ®Google Scholar
• Chválová K, Brabec V, Kaspárková J. Mechanism of the formation of DNA-protein cross-links by antitumor cisplatin. Nucleic Acids Res 2007; 35:1812 - 21; http://dx.doi.org/10.1093/nar/gkm032; PMID: 17329374
   PubMed Web of Science ®Google Scholar
• Lønning PE. Molecular basis for therapy resistance. Mol Oncol 2010; 4:284 - 300; http://dx.doi.org/10.1016/j.molonc.2010.04.005; PMID: 20466604
   PubMed Web of Science ®Google Scholar
• Mocellin S. Editorial: cancer chemoresistance and DNA repair. Curr Med Chem 2012; 19:3857; http://dx.doi.org/10.2174/092986712802002545; PMID: 22788737
   PubMed Web of Science ®Google Scholar
• Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434:864 - 70; http://dx.doi.org/10.1038/nature03482; PMID: 15829956
   PubMed Web of Science ®Google Scholar
• Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr., Kastrinakis NG, Levy B, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434:907 - 13; http://dx.doi.org/10.1038/nature03485; PMID: 15829965
   PubMed Web of Science ®Google Scholar
• Bartek J, Lukas J, Bartkova J. DNA damage response as an anti-cancer barrier: damage threshold and the concept of ‘conditional haploinsufficiency’. Cell Cycle 2007; 6:2344 - 7; http://dx.doi.org/10.4161/cc.6.19.4754; PMID: 17700066
   PubMed Web of Science ®Google Scholar
• Li SX, Sjolund A, Harris L, Sweasy JB. DNA repair and personalized breast cancer therapy. Environ Mol Mutagen 2010; 51:897 - 908; http://dx.doi.org/10.1002/em.20606; PMID: 20872853
   PubMed Web of Science ®Google Scholar
• Quiros S, Roos WP, Kaina B. Rad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs. PLoS One 2011; 6:e27183; http://dx.doi.org/10.1371/journal.pone.0027183; PMID: 22073281
   PubMed Web of Science ®Google Scholar
• Yadav A, Kumar B, Teknos TN, Kumar P. Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. Mol Cancer Ther 2011; 10:1241 - 51; http://dx.doi.org/10.1158/1535-7163.MCT-11-0004; PMID: 21551262
   PubMed Web of Science ®Google Scholar
• Chernikova SB, Game JC, Brown JM. Inhibiting homologous recombination for cancer therapy. Cancer Biol Ther 2012; 13:61 - 8; http://dx.doi.org/10.4161/cbt.13.2.18872; PMID: 22336907
   PubMed Web of Science ®Google Scholar
• Fleck O, Nielsen O. DNA repair. J Cell Sci 2004; 117:515 - 7; http://dx.doi.org/10.1242/jcs.00952; PMID: 14730007
   PubMed Web of Science ®Google Scholar
• Xie A, Kwok A, Scully R. Role of mammalian Mre11 in classical and alternative nonhomologous end joining. Nat Struct Mol Biol 2009; 16:814 - 8; http://dx.doi.org/10.1038/nsmb.1640; PMID: 19633669
   PubMed Web of Science ®Google Scholar
• Lamarche BJ, Orazio NI, Weitzman MD. The MRN complex in double-strand break repair and telomere maintenance. FEBS Lett 2010; 584:3682 - 95; http://dx.doi.org/10.1016/j.febslet.2010.07.029; PMID: 20655309
   PubMed Web of Science ®Google Scholar
• Heikkinen K, Rapakko K, Karppinen SM, Erkko H, Knuutila S, Lundán T, Mannermaa A, Børresen-Dale AL, Borg A, Barkardottir RB, et al. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis 2006; 27:1593 - 9; http://dx.doi.org/10.1093/carcin/bgi360; PMID: 16474176
   PubMed Web of Science ®Google Scholar
• Hsu HM, Wang HC, Chen ST, Hsu GC, Shen CY, Yu JC. Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex. Cancer Epidemiol Biomarkers Prev 2007; 16:2024 - 32; http://dx.doi.org/10.1158/1055-9965.EPI-07-0116; PMID: 17932350
   PubMed Web of Science ®Google Scholar
• Heikkinen K, Karppinen SM, Soini Y, Mäkinen M, Winqvist R. Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility. J Med Genet 2003; 40:e131; http://dx.doi.org/10.1136/jmg.40.12.e131; PMID: 14684699
   PubMed Web of Science ®Google Scholar
• Bartkova J, Tommiska J, Oplustilova L, Aaltonen K, Tamminen A, Heikkinen T, Mistrik M, Aittomäki K, Blomqvist C, Heikkilä P, et al. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol 2008; 2:296 - 316; http://dx.doi.org/10.1016/j.molonc.2008.09.007; PMID: 19383352
   PubMed Web of Science ®Google Scholar
• Angèle S, Treilleux I, Brémond A, Tanière P, Hall J. Altered expression of DNA double-strand break detection and repair proteins in breast carcinomas. Histopathology 2003; 43:347 - 53; http://dx.doi.org/10.1046/j.1365-2559.2003.01713.x; PMID: 14511253
   PubMed Web of Science ®Google Scholar
• Söderlund K, Stål O, Skoog L, Rutqvist LE, Nordenskjöld B, Askmalm MS. Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer. Int J Radiat Oncol Biol Phys 2007; 68:50 - 8; http://dx.doi.org/10.1016/j.ijrobp.2006.12.005; PMID: 17337132
   PubMed Web of Science ®Google Scholar
• Figures MR, Wobb J, Araki K, Liu T, Xu L, Zhu H, O’Malley BW Jr., Li D. Head and neck squamous cell carcinoma targeted chemosensitization. Otolaryngol Head Neck Surg 2009; 141:177 - 83; http://dx.doi.org/10.1016/j.otohns.2009.04.024; PMID: 19643248
   PubMed Web of Science ®Google Scholar
• Abuzeid WM, Jiang X, Shi G, Wang H, Paulson D, Araki K, Jungreis D, Carney J, O’Malley BW Jr., Li D. Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy. J Clin Invest 2009; 119:1974 - 85; http://dx.doi.org/10.1172/JCI33816; PMID: 19487811
   PubMed Web of Science ®Google Scholar
• Fan S, Smith ML, Rivet DJ 2nd, Duba D, Zhan Q, Kohn KW, Fornace AJ Jr., O’Connor PM. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995; 55:1649 - 54; PMID: 7712469
   PubMed Web of Science ®Google Scholar
• Zhong H, Bryson A, Eckersdorff M, Ferguson DO. Rad50 depletion impacts upon ATR-dependent DNA damage responses. Hum Mol Genet 2005; 14:2685 - 93; http://dx.doi.org/10.1093/hmg/ddi302; PMID: 16087684
   PubMed Web of Science ®Google Scholar
• Zhong ZH, Jiang WQ, Cesare AJ, Neumann AA, Wadhwa R, Reddel RR. Disruption of telomere maintenance by depletion of the MRE11/RAD50/NBS1 complex in cells that use alternative lengthening of telomeres. J Biol Chem 2007; 282:29314 - 22; http://dx.doi.org/10.1074/jbc.M701413200; PMID: 17693401
   PubMed Web of Science ®Google Scholar
• Icli F, Akbulut H, Uner A, Yalcin B, Baltali E, Altinbas M, Coşkun S, Komurcu S, Erkisi M, Demirkazik A, et al, Oncology Group. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. Br J Cancer 2005; 92:639 - 44; http://dx.doi.org/10.1038/sj.bjc.6602388; PMID: 15726120
   PubMed Web of Science ®Google Scholar
• Lopez-Camarillo C, Marchat LA, Rodriguez-Cuevas S, Arechaga-Ocampo E, Perez-Plasencia C, Castañeda-Ortiz EJ, Fonseca MA. DNA repair as a novel therapeutic target in breast cancer. In DNA Repair: New Research. Edited by Nova Science Publishers, Inc. New York, 2011.
   Google Scholar
• Williams GJ, Lees-Miller SP, Tainer JA. Mre11-Rad50-Nbs1 conformations and the control of sensing, signaling, and effector responses at DNA double-strand breaks. DNA Repair (Amst) 2010; 9:1299 - 306; http://dx.doi.org/10.1016/j.dnarep.2010.10.001; PMID: 21035407
   PubMed Web of Science ®Google Scholar
• Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, Pommier Y. GammaH2AX and cancer. Nat Rev Cancer 2008; 8:957 - 67; http://dx.doi.org/10.1038/nrc2523; PMID: 19005492
   PubMed Web of Science ®Google Scholar
• Fonseca-Sánchez MA, Rodríguez Cuevas S, Mendoza-Hernández G, Bautista-Piña V, Arechaga Ocampo E, Hidalgo Miranda A, Quintanar Jurado V, Marchat LA, Alvarez-Sánchez E, Pérez Plasencia C, et al. Breast cancer proteomics reveals a positive correlation between glyoxalase 1 expression and high tumor grade. Int J Oncol 2012; 41:670 - 80; PMID: 22614840
   PubMed Web of Science ®Google Scholar